艾迪注射液对非小细胞肺癌化疗患者外周血T淋巴细胞影响的系统评价  

Effect of Aidi injection on T lymphocytes in peripheral blood of NSCLC patients with chemotherapy:a systematic review

作　　者：肖政 汪成琼 孙永苹 田应彪 冯继红 姚新生[3] 

机构地区：[1]遵义医学院附属医院遵义医学院循证医学中心,贵州遵义563003 [2]遵义医学院第二临床学院,广东珠海519100 [3]遵义医学院免疫学教研室,贵州遵义563003

出　　处：《安徽医学》2017年第10期1250-1255,共6页Anhui Medical Journal

基　　金：贵州省科技计划项目[黔科合LH字(2016)7485号];遵义医学院博士启动基金(项目编号:F-617);贵州省哲学社会科学规划基金(项目编号:14GZYB58)

摘　　要：目的系统评价艾迪注射液辅助化疗非小细胞肺癌(NSCLC)患者前后,外周血T淋巴细胞的动态变化特征,为科学合理制订用药策略提供依据。方法系统检索CBM、CNKI、维普、万方、ISI、Pubmed、Embase及Cochrane library等数据库,采用加拿大卫生经济研究所制定的病例系列方法学质量工具评价纳入研究方法学质量,meta分析或描述性分析提取数据。结果纳入22个自身前后对照研究,共867例中晚期NSCLC患者,纳入研究质量一般;meta分析或描述性分析表明艾迪辅助化疗后患者外周血CD3^+T细胞、CD4^+T细胞、CD8^+T细胞百分比,CD4^+/CD8^+T细胞比值在1~4周及6周升高,8~12周恢复到治疗前状态,甚至降低。结论艾迪注射液辅助化疗能提高NSCLC患者外周血T淋巴细胞水平,化疗后1~4周及6周处于升高状态,8周可恢复至化疗前状态,12周可比化疗前更低。Objective To provide the evidences for the rational drug use strategies via a systematic review of the dynamic character-istics of T lymphocytes in peripheral blood before and after Aidi injection adjuvant chemotherapy in NSCLC. Metliods We retrieved all relat-ed studies in CBM,CNKI,VIP, Wanfang, Pubmed and Embase, evaluated their quality by Quality Appraisal Tool for and analyzed all data by meta - analysis or descriptive analysis. Results Twenty - two self - control studies involving 867 non - small celllung cancers were included,with general methodological quality in most trials. Meta analysis and descriptive analysis showed that after Aidi injection adjuvant chemotherapy,the percentages of CD3 ＋ T cells, CD4 ＋ T cells,CD8 ＋ T cells and CD4 ＋ /CD8 ＋ T cell ratio of peripheral blood increased in 1 -4 or 6 weeks in NSCLC. These indexes decreased to the state before treatment in 8 or 12 weeks. Conclusion Aidi in-jection can significantly improve the level of peripheral blood T lymphocytes in 4 - 6 weeks ater treatment, which may be restored to the state before treatment in 8 weeks and may be lower thanthat before treatment in 12 weeks.

关 键 词：艾迪注射液 非小细胞肺癌 T淋巴细胞 系统评价 

分 类 号：R734.2[医药卫生—肿瘤]